Targeted cancer medicines have made significant advancements in the medical field in recent years. In addition to these, Actinium-225 (Ac-225) has become recognised as a promising isotope in the realm of targeted alpha therapy (TAT).
Actinium-225 (Ac-225) is a radioisotope with potential applications in cancer treatment. When radioisotope is coupled to a targeting molecule, such as an antibody or peptides, it binds to specific antigens on cancer cells, thus causing tumour kill.
There are various benefits associated with Ac-225 therapy’s tailored nature
Because of the short radiation paths and high radiation energy transfer, alpha-emitting isotopes like actinium-225 have great potential for treating cancer since they can effectively destroy cancer cells while sparing healthy cells.
High-energy alpha particles released by the decaying isotope break DNA in the cancer cell, causing irreversible damage
Conclusively, Actinium-225 shows great promise in targeted alpha therapy for cancer treatment, but its limited availability due to its rarity and the challenges in production remain significant hurdles for its widespread use in medical applications.
EN
中文
IDN